You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美FDA專家組通過莫德納(MRNA.US)新冠疫苗於6至17歲人士使用
阿思達克 06-15 16:06
美國食品及藥物管理局(FDA)獨立免疫專家小組批准莫德納(MRNA.US)新冠疫苗可用於6至17歲未成年人。小組一致通過有關決定,並同意6至11歲小童接種劑量為成年人一半,12至17歲青少年劑量則與成年人相同。 美國食品及藥物管理局疫苗辦公室高層指,莫德納的新冠疫苗在Omricon變種流行前已進行臨床測試,因此未知該疫苗目前的防疫攻效。但第三劑莫德納疫苗於其他年齡組別上顯示能顯著增加對Omicron變種的防疫。莫德納擬稍後提供更多第三劑疫苗數據。 莫德納疫苗接種在12至17歲青少年身上後,在面對Alpha變種及原來新冠病毒的估計有效率為90%。在6至11歲小身上接種後,面對Delta變種的估計有效預防率為76%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account